ObvioHealth Announces Scott Clark as Chief Commercial Officer

NEW YORK – August 2, 2021 - ObvioHealth, a global Virtual Research Organization (VRO), today announces it has appointed Scott Clark as its Chief Commercial Officer. Scott has had a distinguished and successful 25-year career in developing successful commercial strategies for global enterprises in the pharmaceutical, biotechnology, healthcare and technology industries. 

Scott started his career at SmithKline Beecham, before moving to Pfizer where he developed a lucrative OTC division. He also developed two new business entities for Quintiles, including the eSolutions Group, a division at the frontier of the digital revolution in clinical research. He subsequently developed and implemented the marketing, sales and commercial strategies for several CROs driving their revenue to record levels. He comes to ObvioHealth at crucial moment in its growth trajectory.

“ObvioHealth is the right company with the right solution at the right time to help deliver on the promise of a more efficient and effective clinical process,” Scott said. “Their platform is already transforming the patient experience and their new strategy leveraging real world data and evidence has the potential to move beyond ‘one-off’ clinical trials to help drive new therapies to market faster. That is a game-changer for this industry, and I’m excited to be a part of it.” 

“Scott’s years of experience and deep understanding of the clinical research industry will be an asset to our team,” said Ivan Jarry, CEO of ObvioHealth. “His role will reinforce our commercial strategy by helping to build alliances with partners, CROs and device companies to drive ObvioHealth’s success. He will work with our sales, marketing and product development teams to ensure our offering meets the needs of the market, as the demand for decentralized clinical trials soars.”

Visit www.obviohealth.com for more information. 

About ObvioHealth

ObvioHealth is an end-to-end Virtual Research Organization (VRO) that delivers better data to sponsors and an easier clinical trial experience for participants. The company developed and launched one of the first DCT apps, downloadable on smartphones enabling people to participate in clinical trials from the comfort of their homes. In the 4 years since launch, the company has been awarded nearly 40 studies from 28 blue chip clients, implemented in 28 countries, in16 different therapeutic areas. For more information, visit https://www.obviohealth.com.